Antinociceptive activity of Copaifera officinalis Jacq. L oil and kaurenoic acid in mice.
Analgesics
/ pharmacology
Animals
Anti-Inflammatory Agents
/ pharmacology
Capsaicin
/ pharmacology
Diterpenes
/ pharmacology
Fabaceae
/ chemistry
Female
Freund's Adjuvant
/ pharmacology
Hyperalgesia
/ drug therapy
Male
Mice
Nociception
/ drug effects
Oils, Volatile
/ pharmacology
Pain Measurement
/ methods
Plant Extracts
/ pharmacology
Capsaicin
Copaiba oil
Inflammatory pain
Morphine
Naloxone
Nociception
Journal
Inflammopharmacology
ISSN: 1568-5608
Titre abrégé: Inflammopharmacology
Pays: Switzerland
ID NLM: 9112626
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
19
12
2018
accepted:
16
03
2019
pubmed:
18
5
2019
medline:
10
1
2020
entrez:
18
5
2019
Statut:
ppublish
Résumé
Copaifera officinalis L. possesses traditional uses as an analgesic, anti-inflammatory, and antiseptic. However, until now the antinociceptive effect and the mechanism of action were not described for Copaifera officinalis L. oil and no compound present in this oil was identified to be responsible for its biological effects. The goal of this study was to identify the presence of kaurenoic acid in Copaifera officinalis oil and investigate its antinociceptive effect, mechanism of action, and possible adverse effects in mice. The quantification of kaurenoic acid in Copaifera officinalis oil was done by HPLC-DAD technique. Male and female albino Swiss mice (25-35 g) were used to test the antinociceptive effect of Copaifera officinalis (10 mg/kg, intragastric) or kaurenoic acid (1 mg/kg) in the tail-flick test, intraplantar injection of capsaicin, allyl isothiocyanate (AITC) or complete Freund's adjuvant (CFA). Copaifera officinalis oil and kaurenoic acid caused the antinociceptive effect in the tail-flick test in a dose-dependent manner, and their effect was reversed by naloxone (an opioid antagonist). Copaifera officinalis oil or kaurenoic acid reduced the nociception caused by capsaicin or AITC and produced an anti-allodynic effect in the CFA model (after acute or repeated administration for 7 days). Possible adverse effects were also observed, and non-detectable adverse effect was observed for the intragastric administration of Copaiba officinalis oil or kaurenoic acid and in the same way, the treatments were neither genotoxic nor mutagenic at the doses tested. Thus, Copaiba officinalis oil, and kaurenoic acid possess antinociceptive action without adverse effects.
Identifiants
pubmed: 31098702
doi: 10.1007/s10787-019-00588-3
pii: 10.1007/s10787-019-00588-3
doi:
Substances chimiques
Analgesics
0
Anti-Inflammatory Agents
0
Diterpenes
0
Oils, Volatile
0
Plant Extracts
0
kaurenoic acid
6730-83-2
Freund's Adjuvant
9007-81-2
Capsaicin
S07O44R1ZM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
829-844Références
Mutat Res. 1990 Jul;239(1):29-80
pubmed: 2195332
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4442-7
pubmed: 20147620
Biochem Pharmacol. 2011 Feb 15;81(4):544-51
pubmed: 21087598
J Pharmacol Exp Ther. 2003 Jan;304(1):56-62
pubmed: 12490575
Annu Rev Med. 2016;67:433-51
pubmed: 26332001
Pain Ther. 2018 Jun;7(1):59-75
pubmed: 29594972
Planta Med. 2013 Jul;79(11):952-8
pubmed: 23824551
Mol Pharmacol. 2013 Apr;83(4):723-8
pubmed: 23249538
Exp Cell Res. 1988 Mar;175(1):184-91
pubmed: 3345800
Annu Rev Pharmacol Toxicol. 1980;20:441-62
pubmed: 7387124
Pain. 2018 Oct;159(10):1989-2001
pubmed: 29847470
Neuroscience. 2012 Jun 1;211:39-50
pubmed: 22244975
Environ Mol Mutagen. 2000;35(3):206-21
pubmed: 10737956
J Ethnopharmacol. 2007 Feb 12;109(3):486-92
pubmed: 17029841
J Chromatogr Sci. 2015 Oct;53(9):1557-61
pubmed: 25977240
Int J Pharm Compd. 2016 Jan-Feb;20(1):58-62
pubmed: 27125055
J Ethnopharmacol. 1998 May;61(1):85-9
pubmed: 9687086
Food Chem Toxicol. 2006 Mar;44(3):388-92
pubmed: 16182426
J Ethnopharmacol. 2010 Mar 2;128(1):177-83
pubmed: 20064592
Br J Pharmacol. 2014 May;171(10):2552-67
pubmed: 24206166
Biochim Biophys Acta. 2009 Aug;1790(8):793-9
pubmed: 19397953
Prog Neurobiol. 2002 Apr;66(6):355-474
pubmed: 12034378
Environ Mol Mutagen. 1997;30(2):139-46
pubmed: 9329638
Nat Neurosci. 2013 Feb;16(2):183-92
pubmed: 23292683
J Ethnopharmacol. 2017 Jan 4;195:283-297
pubmed: 27864110
Pain Physician. 2011 Mar-Apr;14(2):145-61
pubmed: 21412369
Oxid Med Cell Longev. 2015;2015:536962
pubmed: 26457127
Arthritis Rheum. 2004 May;50(5):1677-85
pubmed: 15146439
Vascul Pharmacol. 2002 Dec;39(6):303-7
pubmed: 14567068
Phytother Res. 2000 Sep;14(6):401-18
pubmed: 10960893
Evid Based Complement Alternat Med. 2017;2017:8350320
pubmed: 28194218
J Nat Prod. 2012 May 25;75(5):896-904
pubmed: 22574649
Curr Opin Pharmacol. 2015 Jun;22:18-23
pubmed: 25725213
J Nat Prod. 2009 Apr;72(4):608-12
pubmed: 19231884
Arzneimittelforschung. 1988 May;38(5):686-90
pubmed: 3415709
Neuropharmacology. 2013 Oct;73:261-73
pubmed: 23791558
Naunyn Schmiedebergs Arch Pharmacol. 2017 Nov;390(11):1163-1172
pubmed: 28821921
Tissue Cell. 2010 Aug;42(4):266-72
pubmed: 20655561
Life Sci. 2008 Nov 21;83(21-22):739-46
pubmed: 18848839
Mutagenesis. 2017 Jul 1;32(4):411-415
pubmed: 28472308
Basic Clin Pharmacol Toxicol. 2004 Aug;95(2):53-8
pubmed: 15379780
Pharmacol Res. 2016 Oct;112:4-29
pubmed: 26812486
Exp Parasitol. 2011 Oct;129(2):145-51
pubmed: 21771592
Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):679-89
pubmed: 24722818
Pain. 1987 Mar;28(3):379-93
pubmed: 3574965
Neuroscience. 2008 Mar 18;152(2):511-20
pubmed: 18272293
Mutat Res. 2000 Nov 20;455(1-2):155-66
pubmed: 11113474
Fitoterapia. 2001 Jan;72(1):40-5
pubmed: 11163939
Eur J Pharmacol. 2008 Feb 26;581(1-2):86-96
pubmed: 18190906
Phytother Res. 2002 Dec;16(8):737-9
pubmed: 12458476
J Integr Med. 2017 Sep;15(5):379-387
pubmed: 28844215
Neuropharmacology. 1992 Dec;31(12):1279-85
pubmed: 1281912
J Pharmacol Exp Ther. 2012 Nov;343(2):258-69
pubmed: 22837009
Br J Pharmacol. 2015 Jul;172(13):3189-93
pubmed: 25964986
Pain. 1983 Jun;16(2):109-10
pubmed: 6877845